- Home
- PLX vs STHO Comparison
PLX vs STHO Comparison
Compare PLX & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- STHO
- Stock Information
- Founded
- PLX 1993
- STHO N/A
- Country
- PLX United States
- STHO United States
- Employees
- PLX N/A
- STHO N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- STHO Real Estate
- Sector
- PLX Health Care
- STHO Real Estate
- Exchange
- PLX Nasdaq
- STHO Nasdaq
- Market Cap
- PLX 127.4M
- STHO 113.4M
- IPO Year
- PLX 1998
- STHO N/A
- Fundamental
- Price
- PLX $1.91
- STHO $8.88
- Analyst Decision
- PLX Strong Buy
- STHO
- Analyst Count
- PLX 1
- STHO 0
- Target Price
- PLX $15.00
- STHO N/A
- AVG Volume (30 Days)
- PLX 705.4K
- STHO 43.4K
- Earning Date
- PLX 11-13-2025
- STHO 11-04-2025
- Dividend Yield
- PLX N/A
- STHO N/A
- EPS Growth
- PLX N/A
- STHO N/A
- EPS
- PLX 0.08
- STHO N/A
- Revenue
- PLX $61,948,000.00
- STHO $113,989,000.00
- Revenue This Year
- PLX $14.53
- STHO N/A
- Revenue Next Year
- PLX $75.77
- STHO N/A
- P/E Ratio
- PLX $24.60
- STHO N/A
- Revenue Growth
- PLX 62.79
- STHO N/A
- 52 Week Low
- PLX $0.99
- STHO $6.06
- 52 Week High
- PLX $3.10
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- PLX 70.20
- STHO 67.96
- Support Level
- PLX $1.52
- STHO $8.71
- Resistance Level
- PLX $1.69
- STHO $9.09
- Average True Range (ATR)
- PLX 0.08
- STHO 0.22
- MACD
- PLX 0.03
- STHO 0.01
- Stochastic Oscillator
- PLX 91.67
- STHO 71.33
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.